Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Metastatic Breast Cancer × Alpelisib × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 2 Breast Neoplasms 2 Vascular Malformations 1 Skin Diseases, Vascular 1 Recurrence 1 Neoplasm Metastasis 1 Lymphatic Abnormalities 1 Lymphangioma, Cystic 1 Lymphangioma 1 HER2-positive Metastatic Breast Cancer 1 Fallopian Tube Neoplasms 1 Endometrial Neoplasms 1 Arteriovenous Malformations 1

Interventions

tucatinib 1 Fulvestrant 1 Alpelisib 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Criterium, Inc.

Phase 1/2 Active not recruiting

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡